Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0KBML)

Drug Name

REGN-COV2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting COVID-19 spike glycoprotein (S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[3]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[4]
GSK4182136	DMYH2FI	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved in EU	[5]
LY-CoV555	DM6LVCQ	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[6]
JS016	DMGEZVF	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2	[7]
REGN3051	DM7LIV2	Coronavirus infection	1D92	Phase 1	[8]
REGN3048	DM0E3ZG	Coronavirus infection	1D92	Phase 1	[8]
GSK4182137	DMJJW2Y	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[5]
MERS-4	DMS6KT8	Coronavirus infection	1D92	Preclinical	[9]
MERS-27	DMVGIB4	Coronavirus infection	1D92	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04852978) COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers. U.S. National Institutes of Health.
2	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251.
3	Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020.
4	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline
6	Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189.
7	Clinical pipeline report, company report or official report of Lilly.
8	Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.
9	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.